Scientists boost potential of passive immunization against HIV

This image shows the atomic level protein structure of the antibody VRC01 (blue and green) binding to HIV (grey and red). The precise site of VRC01-HIV binding (red) is a subset of the area of viral attachment to the primary immune cells HIV infects. Credit: NIAID VRC

Scientists are pursuing injections or intravenous infusions of broadly neutralizing HIV antibodies (bNAbs) as a strategy for preventing HIV infection. This technique, called passive immunization, has been shown to protect monkeys from a monkey form of HIV called simian human immunodeficiency virus, or SHIV. To make passive immunization a widely feasible HIV prevention option for people, scientists want to modify bNAbs such that a modest amount of them is needed only once every few months.

To that end, an NIH-led team of scientists has mutated the powerful anti-HIV bNAb called VRC01 so that, once infused into monkeys, it lasts three times longer in blood than unmutated VRC01, collects in rectal mucosal tissue, and persists there more than twice as long as unmutated VRC01. Concentrating anti-HIV bNAbs at mucosal surfaces of the rectum and vagina, the subject of additional study, is critical for blocking sexual transmission of HIV.

In addition, the scientists found, a low-dose infusion of mutated VRC01 protected monkeys against SHIV infection more effectively than a low-dose infusion of unmutated VRC01.

The mutation works by enhancing VRC01's ability to bind to a cellular protein that prevents the antibody from degrading inside cells and influences how frequently the antibody reaches mucosal surfaces and stays there, the researchers report. This finding may inform antibody-based prevention strategies against not only HIV but also other viruses that invade the body at mucosal surfaces, including rotavirus, poliovirus, norovirus and influenza virus.

Next, the researchers will test infusions of mutated VRC01 in people to learn if it concentrates in mucosal tissues and persists there and in blood for an extended period.

More information: S-Y Ko, et al. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature, DOI: 10.1038/nature13612 (2014).

Related Stories

New research offers hope for HIV vaccine development

date Aug 13, 2014

In a scientific discovery that has significant implications for HIV vaccine development, collaborators at the Boston University School of Medicine (BUSM) and Duke University School of Medicine have uncovered ...

Recommended for you

Potential new HIV therapy seen in immune cells

date 12 hours ago

A research team led by Weill Cornell Medical College scientists has discovered a way to limit replication of the most common form of HIV at a key moment when the infection is just starting to develop. The ...

More secondary schooling reduces HIV risk

date 16 hours ago

Longer secondary schooling substantially reduces the risk of HIV infection—especially for girls—and could be a very cost-effective way to halt the spread of the virus, according to researchers from Harvard ...

Bill Gates hopeful of AIDS vaccine in 10 years

date Jun 26, 2015

Billionaire and philanthropist Bill Gates, who spends millions of dollars on AIDS drug development, said Friday he hoped for a vaccine against the disease within the next decade as a cure remains far off.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.